Development of a T Cell Engineering Platform for Fully Individualized Neoantigen-Specific TCR Therapy

Development of a T Cell Engineering Platform for Fully Individualized Neoantigen-Specific TCR Therapy

Explore a 34-minute webinar presented by Dr. Xiangjun Kong, Principal Scientist at Neogene Therapeutics, on the development of a T cell engineering platform for individualized neoantigen-specific TCR therapy. Gain insights into a promising new immunotherapy approach involving adoptive transfer of T cell receptor (TCR)-edited T cells targeting cancer neoantigens. Learn about the high-throughput, patient-specific platform developed to identify neoantigen-reactive TCRs. Discover Dr. Kong's extensive research background in functional screening, genome editing technologies, and novel targeted and immune therapy strategies for cancer. Understand the potential impact of this innovative approach on personalized cancer treatment.